Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* low back pain for 3 months or longer, confirmed by radiographic evidence.~* receiving a stable dose of an opioid analgesic for low back pain.~Exclusion Criteria:~* taking more than 80 mg per day of oral morphine sulfate or equivalent within 30 days of enrollment.~* requiring frequent analgesic therapy for chronic condition(s), in addition to low back pain.~Other protocol-specific exclusion/inclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BTDS 5 (Type: ACTIVE_COMPARATOR): Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
- BTDS 20 (Type: EXPERIMENTAL): Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
- Oxycodone Immediate-Release (Type: EXPERIMENTAL): Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).